August 18, 2015.
The U.S. Food and Drug Administration (FDA) has approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Prior to Addyi’s approval, there were no FDA-approved treatments for sexual desire disorders in men or women. The treatment has become popularly known as "female viagra".
HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition.
Addyi is being approved with a risk evaluation and mitigation strategy (REMS), which FDA is requiring because of the increased risk of severe hypotension and syncope due to the interaction between Addyi and alcohol. The drug is also being approved with a Boxed Warning to highlight the risks of severe hypotension and syncope in patients who drink alcohol during treatment with Addyi, in those who also use moderate or strong CYP3A4 inhibitors, and in those who have liver impairment.
FDA reports that it "has recognized for some time the challenges involved in developing treatments for female sexual dysfunction". Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER) said “Today’s approval provides women distressed by their low sexual desire with an approved treatment option".
Source: FDA
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.